Market Closed -
Nasdaq
16:00:00 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
16.86
USD
|
-0.06%
|
|
+8.08%
|
+13.23%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,435
|
870.3
|
459.3
|
741.8
|
851.4
|
-
|
-
|
Enterprise Value (EV)
1 |
3,000
|
506.7
|
419.9
|
729
|
852.4
|
865.3
|
808.5
|
P/E ratio
|
-31.2
x
|
-10.4
x
|
-3.72
x
|
-3.98
x
|
-5.15
x
|
-5.97
x
|
-6.27
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,906
x
|
-
|
-
|
-
|
-
|
-
|
78.3
x
|
EV / Revenue
|
2,538
x
|
-
|
-
|
-
|
-
|
-
|
74.4
x
|
EV / EBITDA
|
-69
x
|
-6.07
x
|
-3.3
x
|
-4.3
x
|
-5.11
x
|
-4.89
x
|
-4.88
x
|
EV / FCF
|
-78.3
x
|
-7.37
x
|
-4.63
x
|
-
|
-7.16
x
|
-6.56
x
|
-3.83
x
|
FCF Yield
|
-1.28%
|
-13.6%
|
-21.6%
|
-
|
-14%
|
-15.3%
|
-26.1%
|
Price to Book
|
7.99
x
|
2.4
x
|
1.74
x
|
3.92
x
|
27.3
x
|
-80.4
x
|
22.2
x
|
Nbr of stocks (in thousands)
|
39,845
|
40,500
|
40,755
|
49,819
|
50,499
|
-
|
-
|
Reference price
2 |
86.20
|
21.49
|
11.27
|
14.89
|
16.86
|
16.86
|
16.86
|
Announcement Date
|
21-03-18
|
22-02-28
|
23-03-09
|
24-03-07
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.796
|
1.182
|
-
|
-
|
-
|
-
|
-
|
10.87
|
EBITDA
1 |
-
|
-43.46
|
-83.5
|
-127.1
|
-169.4
|
-166.8
|
-176.8
|
-165.6
|
EBIT
1 |
-
|
-43.66
|
-83.56
|
-127.4
|
-170.3
|
-172.8
|
-172.6
|
-187.2
|
Operating Margin
|
-
|
-3,693.99%
|
-
|
-
|
-
|
-
|
-
|
-1,722.31%
|
Earnings before Tax (EBT)
1 |
-
|
-45.5
|
-83.48
|
-123.4
|
-160.8
|
-165.2
|
-150.4
|
-168.1
|
Net income
1 |
-
|
-45.74
|
-83.46
|
-123.5
|
-160.8
|
-173
|
-171.1
|
-190.8
|
Net margin
|
-
|
-3,869.71%
|
-
|
-
|
-
|
-
|
-
|
-1,755.34%
|
EPS
2 |
-1.150
|
-2.760
|
-2.070
|
-3.030
|
-3.740
|
-3.271
|
-2.826
|
-2.690
|
Free Cash Flow
1 |
-
|
-38.32
|
-68.77
|
-90.65
|
-
|
-119
|
-132
|
-211
|
FCF margin
|
-
|
-3,241.96%
|
-
|
-
|
-
|
-
|
-
|
-1,940.87%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-05-05
|
21-03-18
|
22-02-28
|
23-03-09
|
24-03-07
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-33.7
|
-36.59
|
-32.11
|
-
|
-
|
-
|
-
|
-35.38
|
-39.6
|
-48.24
|
-42.98
|
-
|
EBIT
1 |
-24.58
|
-28.47
|
-24.75
|
-33.79
|
-36.68
|
-32.22
|
-32.2
|
-36.78
|
-53.28
|
-48.02
|
-42.47
|
-42.66
|
-44.1
|
-43.59
|
-41.62
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-24.57
|
-28.46
|
-24.53
|
-32.92
|
-35.32
|
-30.64
|
-30.18
|
-34.16
|
-50.99
|
-45.47
|
-42.24
|
-41.22
|
-40.97
|
-41.02
|
-40.35
|
Net income
1 |
-24.57
|
-28.44
|
-24.53
|
-32.92
|
-35.32
|
-30.71
|
-30.18
|
-34.16
|
-50.99
|
-45.47
|
-43.59
|
-43.18
|
-43.18
|
-43.41
|
-40.35
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6100
|
-0.7000
|
-0.6000
|
-0.8100
|
-0.8700
|
-0.7500
|
-0.7400
|
-0.8400
|
-1.240
|
-0.9300
|
-0.8358
|
-0.8362
|
-0.8071
|
-0.7980
|
-0.7550
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-11
|
22-02-28
|
22-05-09
|
22-08-08
|
22-11-08
|
23-03-09
|
23-05-11
|
23-08-10
|
23-11-13
|
24-03-07
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
0.95
|
13.9
|
-
|
Net Cash position
1 |
-
|
434
|
364
|
39.4
|
12.8
|
-
|
-
|
42.9
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.005708
x
|
-0.0786
x
|
-
|
Free Cash Flow
1 |
-
|
-38.3
|
-68.8
|
-90.7
|
-
|
-119
|
-132
|
-211
|
ROE (net income / shareholders' equity)
|
-
|
-25.5%
|
-21.1%
|
-39.4%
|
-71%
|
-144%
|
-1,804%
|
-832%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
10.80
|
8.940
|
6.470
|
3.800
|
0.6200
|
-0.2100
|
0.7600
|
Cash Flow per Share
|
-
|
-2.070
|
-1.690
|
-2.190
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.03
|
0.67
|
1.43
|
1.27
|
2
|
1.2
|
2
|
Capex / Sales
|
-
|
2.62%
|
-
|
-
|
-
|
-
|
-
|
18.4%
|
Announcement Date
|
20-05-05
|
21-03-18
|
22-02-28
|
23-03-09
|
24-03-07
|
-
|
-
|
-
|
Last Close Price
16.86
USD Average target price
20.17
USD Spread / Average Target +19.61% Consensus |
1st Jan change
|
Capi.
|
---|
| +13.23% | 851M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|